Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 70Lymphoma 54Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Hodgkin Disease 26Sarcoma 25Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 24Leukemia 19Burkitt Lymphoma 17Multiple Myeloma 16Endometrial Neoplasms 15Neuroblastoma 14Ovarian Neoplasms 12Carcinoma, Hepatocellular 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Liposarcoma 9Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Leiomyosarcoma 8Histiocytoma, Malignant Fibrous 8Urinary Bladder Neoplasms 7Lymphoma, B-Cell, Marginal Zone 7Hemangiosarcoma 7Fibrosarcoma 7Wilms Tumor 6Triple Negative Breast Neoplasms 6Sarcoma, Synovial 6Neurofibrosarcoma 6

Interventions

raltitrexed 1lobaplatin 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Liver, Cancer of, Primary Resectable × Doxorubicin × Clear all
NCT05701436 2023-03-02

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Zhujiang Hospital

Phase 3 Unknown
144 enrolled

Liver, Cancer of, Primary Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡